Therapeutics News and Research

RSS

FDA to review Acorda Therapeutics’ NDA for Fampridine-SR

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the U.S. Food and Drug Administration (FDA) has confirmed that its Peripheral and Central Nervous System Drugs Advisory Committee will review the Company’s New Drug Application (NDA) for Fampridine-SR on October 14, 2009.

26 Aug 2009

Tikcro Technologies announces financial results for the second-quarter ended June 30, 2009

Tikcro Technologies Ltd. (OTC BB: TIKRF) today reported results for the second quarter and six months ended June 30, 2009.

26 Aug 2009

Genvec to use $2.5 million grant from NIAID for the development of novel cell lines

GenVec, Inc. (Nasdaq: GNVC) announced today that it has received a Phase 2 Small Business Innovation and Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to support the development of GenVec's vector production technology.

25 Aug 2009

Raptor Pharmaceuticals raises funds to execute its corporate strategy

Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced that it has raised an aggregate $5 million of gross proceeds through a private placement of units ("August 2009 Private Placement") and through the exercise of warrants (the "Warrant Exchange") originally issued in connection with its May/June 2008 private placement.

25 Aug 2009

Shire collaborates with Santaris Pharma to develop Locked Nucleic Acid technology

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces today that it has entered into a research-based collaboration with Santaris Pharma A/S, a leading player in RNA-based therapeutics, to develop its proprietary Locked Nucleic Acid (LNA) technology in a range of rare diseases, thereby enabling Shire to build on its already strong competitive position for its Human Genetic Therapies (HGT) business.

25 Aug 2009

Cytrx’s study offers a better perception of arimoclomol's mechanism of action in induced animal stroke

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, today announced that study results demonstrated that arimoclomol exhibited both statistically significant neuroprotective and neuroregenerative effects in brain cells of animals induced with stroke, offering important insights into this drug candidate’s mechanism of action.

25 Aug 2009

NanoBusiness 2009 conference to address nanotechnology advancements in various markets

The NanoBusiness Alliance, the world's leading nanotechnology trade association, today announced details of its expanded conference program for the 8th annual NanoBusiness 2009 conference and exhibition, which will held at McCormick Place in Chicago, IL, from September 8 – 10.

25 Aug 2009

Mark Booth joins Orexigen Therapeutics as the Chief Commercial Officer

Orexigen((R)) Therapeutics, Inc. today announced that Mark Booth has joined the Company as Chief Commercial Officer. Mr. Booth brings over 25 years of commercial and business development experience to Orexigen. Most recently he served as President of Takeda Pharmaceuticals North America (TPNA) where he presided over the commercial, medical and scientific affairs, business development and all support functions.

25 Aug 2009

Lpath achieves one of the four Phase 1 objectives by demonstrating its optimized fermentation process

Lpath, Inc., the category leader in lipidomics-based therapeutics, demonstrated commercially acceptable yields in its optimized fermentation process. In doing so, Lpath achieved one of four Phase 1 objectives established by Merck Serono, the exclusive worldwide licensee of ASONEP and Lpath's development partner, and will receive a milestone payment according to the terms of the Merck Serono license agreement.

25 Aug 2009

Phase I/II trial of Amphinex uses photochemical internalisation approach

PCI Biotech Holding ASA, the Norwegian drug delivery company focusing on effective delivery of cancer therapeutics, today announced that the first patient has received treatment in the Phase I/II trial with the lead candidate Amphinex(R), which uses a new approach called photochemical internalisation.

25 Aug 2009

Santaris Pharma to discover and develop new RNA-based medicines for treating rare genetic disorders

Santaris Pharma A/S, a privately-held biopharmaceutical company focused on developing RNA-based drugs targeted to disease-related mRNAs and microRNAs, today announced a multi-year worldwide strategic alliance with Shire plc to discover and develop new RNA-based medicines to treat rare genetic disorders.

24 Aug 2009

Israeli government and a private investment fund Brainstorm Cell Therapeutics to complete pre-clinical studies in ALS

BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), a leading developer of adult stem cell technologies and therapeutics, announced today that the company has secured the funding required to complete pre-clinical trials underway for the treatment of ALS (Amyotrophic Lateral Sclerosis, also known as Lou Gehrig’s disease). The company expects to begin Phase I clinical studies in 2010.

24 Aug 2009

Phase 2 clinical study of Resolvin RX-10045 for dry eye syndrome provides positive data

Resolvyx Pharmaceuticals, Inc., the leading resolvin therapeutics company, today announced positive data from a Phase 2 clinical study evaluating RX-10045, a resolvin administered as a topical eye drop for the treatment of patients with chronic dry eye syndrome.

24 Aug 2009

Cell Therapeutics completes sale of Series 2 Preferred Stock and warrants

Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) (the "Company") today announced the closing of its previously announced sale of $30 million of shares of its Series 2 Preferred Stock and warrants to purchase shares of its common stock in a registered offering to a single institutional investor. The investor has elected to convert all of its shares of Series 2 Preferred Stock and to receive the 18,853,103 shares of the Company's common stock issuable upon such conversion at the closing.

24 Aug 2009

Two key circuits for controlling the cell's ability identified by UCSF researchers

UCSF researchers have identified the two key circuits that control a cell's ability to adapt to changes in its environment, a finding that could have applications ranging from diabetes and autoimmune research to targeted drug development for complex diseases.

24 Aug 2009

Cell Therapeutics' NDA for Pixantrone accepted by the FDA

Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that the U.S. Food and Drug Administration (FDA) has accepted and has filed for review the Company's New Drug Application (NDA) for pixantrone as treatment for relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL). A Prescription Drug User Fee Act (PDUFA) date will be established by the FDA regarding the review of the pixantrone NDA by September 4th 2009.

24 Aug 2009

Cut back in research and development expenses helps to decrease losses in second quarter for Ico Therapeutics

iCo Therapeutics Inc. (TSX-V: ICO) today reported financial results for the quarter ended June 30, 2009. Amounts, unless specified otherwise, are expressed in Canadian dollars and in accordance with Canadian Generally Accepted Accounting Principles (Canadian GAAP).

24 Aug 2009

Mount Sinai Medical Center physicians pioneer a non-surgical procedure for treating LAA

Physicians at The Mount Sinai Medical Center were the first in the country to perform a non-surgical procedure using sutures to tie off a left atrial appendage (LAA), which is the source of blood clots leading to stroke in patients with atrial fibrillation (AFib). AFib is the most common sustained heart-rhythm disorder in the United States.

24 Aug 2009

Researchers develop new ways for splitting dangerous pair of cancer proteins

A research team led by U of T Mississauga scientists has developed a new way to split up a dangerous pair of cancer proteins, a finding that could ultimately lead to chemotherapy that is more effective and has fewer side effects.

21 Aug 2009

TCT Featured Clinical Trials to be presented on September 24 in San Francisco

A series of Featured Clinical Trials will be presented at Transcatheter Cardiovascular Therapeutics (TCT), in addition to late-breaking clinical trials. These featured clinical trials represent groundbreaking research and will yield data and insight that will further the field of interventional cardiology.

21 Aug 2009

Therapeutics News and Research

FDA to review Acorda Therapeutics’ NDA for Fampridine-SR

Tikcro Technologies announces financial results for the second-quarter ended June 30, 2009

Genvec to use $2.5 million grant from NIAID for the development of novel cell lines

Raptor Pharmaceuticals raises funds to execute its corporate strategy

Shire collaborates with Santaris Pharma to develop Locked Nucleic Acid technology

Cytrx’s study offers a better perception of arimoclomol's mechanism of action in induced animal stroke

NanoBusiness 2009 conference to address nanotechnology advancements in various markets

Mark Booth joins Orexigen Therapeutics as the Chief Commercial Officer

Lpath achieves one of the four Phase 1 objectives by demonstrating its optimized fermentation process

Phase I/II trial of Amphinex uses photochemical internalisation approach

Santaris Pharma to discover and develop new RNA-based medicines for treating rare genetic disorders

Israeli government and a private investment fund Brainstorm Cell Therapeutics to complete pre-clinical studies in ALS

Phase 2 clinical study of Resolvin RX-10045 for dry eye syndrome provides positive data

Cell Therapeutics completes sale of Series 2 Preferred Stock and warrants

Two key circuits for controlling the cell's ability identified by UCSF researchers

Cell Therapeutics' NDA for Pixantrone accepted by the FDA

Cut back in research and development expenses helps to decrease losses in second quarter for Ico Therapeutics

Mount Sinai Medical Center physicians pioneer a non-surgical procedure for treating LAA

Researchers develop new ways for splitting dangerous pair of cancer proteins

TCT Featured Clinical Trials to be presented on September 24 in San Francisco

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News